The estimated Net Worth of Adele M. Gulfo is at least 335 千$ dollars as of 20 March 2019. Ms. Gulfo owns over 75 units of Myovant Sciences Ltd stock worth over 2,024$ and over the last 9 years she sold MYOV stock worth over 0$. In addition, she makes 332,662$ as Director、 Interim Chief Commercial Officer at Myovant Sciences Ltd.
Adele has made over 1 trades of the Myovant Sciences Ltd stock since 2019, according to the Form 4 filled with the SEC. Most recently she bought 75 units of MYOV stock worth 4,981$ on 20 March 2019.
The largest trade she's ever made was buying 75 units of Myovant Sciences Ltd stock on 20 March 2019 worth over 4,981$. On average, Adele trades about 2 units every 0 days since 2016. As of 20 March 2019 she still owns at least 75 units of Myovant Sciences Ltd stock.
You can see the complete history of Ms. Gulfo stock trades at the bottom of the page.
Adele M. Gulfo serves as Director, Interim Chief Commercial Officer of the Company. She has served as Chief Business and Commercial Development Officer at Sumitovant Biopharma, Inc., a biopharmaceutical company and a subsidiary of Sumitovant, since December 2019, in which capacity she is responsible for overseeing global business development and commercialization activities across a diverse pipeline. Sumitovant, formed as a wholly-owned subsidiary of Sumitomo Dainippon Pharma, operates five biopharmaceutical companies acquired from Roivant, our former controlling shareholder, in December 2019 and is our majority shareholder. From May 2018 to December 2019, Ms. Gulfo served as Chief of Commercial Development at Roivant, a pharmaceutical company, in which capacity she was responsible for directing business development activities and overseeing commercialization strategies. Prior to joining Roivant in May 2018, Ms. Gulfo served as Executive Vice President and Head of Global Commercial Development for Mylan N.V., a global pharmaceuticals company, from January 2014 to January 2018, in which capacity she was responsible for developing and implementing strategies of marketing and commercialization of biosimilars, branded generic, and specialty pharmaceutical products. Before joining Mylan, Ms. Gulfo spent five years at Pfizer Inc. in a number of executive positions, including President and General Manager, U.S. Primary Care. Ms. Gulfo received her B.S. in Biology from Seton Hall University, and her M.B.A. (with highest honors) in Marketing from Fairleigh Dickinson University-Florham Campus. She studied post-graduate Molecular Biology
As the Director、 Interim Chief Commercial Officer of Myovant Sciences Ltd, the total compensation of Adele Gulfo at Myovant Sciences Ltd is 332,662$. There are 10 executives at Myovant Sciences Ltd getting paid more, with Lynn Seely having the highest compensation of 6,222,670$.
Adele Gulfo is 57, she's been the Director、 Interim Chief Commercial Officer of Myovant Sciences Ltd since 2020. There are 6 older and 7 younger executives at Myovant Sciences Ltd. The oldest executive at Myovant Sciences Ltd is Kathleen Sebelius, 72, who is the Lead Independent Director.
Adele's mailing address filed with the SEC is 5605 CARNEGIE BLVD., SUITE 500, , CHARLOTTE, NC, 28209.
Over the last 8 years, insiders at Myovant Sciences Ltd have traded over 5,780,890$ worth of Myovant Sciences Ltd stock and bought 96,585,963 units worth 2,001,605,371$ . The most active insiders traders include Sciences Ltd. Roivant、Global Investors Lp Viking ...、Andrew Lo. On average, Myovant Sciences Ltd executives and independent directors trade stock every 15 days with the average trade being worth of 25,106,967$. The most recent stock trade was executed by Chemical Co., Ltd.Sumitomo ... on 10 March 2023, trading 51,599,200 units of MYOV stock currently worth 1,393,178,400$.
Myovant Sciences aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. Myovant Sciences has one FDA-approved medicine, ORGOVYX™ (relugolix), for adult patients with advanced prostate cancer. Its lead product candidate, relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg), is under regulatory review in Europe and the U.S. for women with uterine fibroids and is under development for women with endometriosis. Myovant Sciences is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, which has completed a Phase 2a study for female infertility as part of assisted reproduction. Sumitovant Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is its majority shareholder.
Myovant Sciences Ltd executives and other stock owners filed with the SEC include: